ABL Diagnostics: Medtech Star Rises on Profit Surge and Analyst Confidence

WOIPPY, France – May 19, 2026 – By Daniel Howard

In a resounding vote of confidence, equity research firm Allinvest has reiterated its 'BUY' rating for ABL Diagnostics (Euronext: ABLD), maintaining a robust target price of €8.4. The endorsement, which suggests a potential upside of over 123% from its recent closing price, comes on the heels of a stellar 2025 financial report that paints a picture of a company in the midst of a powerful and meticulously executed turnaround.

ABL Diagnostics, a specialist in molecular diagnostics and genotyping, has emerged from a challenging period to post record revenues, a dramatic swing to profitability, and a return to rewarding shareholders. The firm's performance has not only exceeded market expectations but also surpassed Allinvest's own forecasts, solidifying its position as what the research note calls a "unique opportunity within the European Medtech universe."

A Financial Renaissance

The numbers from ABL Diagnostics' 2025 annual report tell a story of profound operational and financial transformation. The company achieved a historic revenue milestone of €6.95 million, a 30.4% increase over the previous year. This growth wasn't a fleeting success but was driven by the strong recurrence of its core genotyping and sequencing business, complemented by new, high-value activities that are beginning to bear fruit.

More impressively, this top-line growth was achieved with remarkable efficiency. The gross margin expanded to 61.7%, up from 58.1% in 2024, thanks to a more profitable product mix and accelerating international sales, which now account for 70% of revenue. This operational leverage triggered a significant swing in profitability. The company posted an operating profit (EBIT) of €0.29 million, a stark reversal from the €0.49 million loss recorded in 2024 and well ahead of Allinvest's projected €0.19 million.

The bottom line was even more striking, with net profit multiplying 3.5 times to reach €0.98 million. This was underpinned by formidable cash generation, with record operational free cash flows of €1.38 million. This influx of cash has allowed ABL Diagnostics to dramatically strengthen its balance sheet, slashing net debt by over 54% to €0.93 million while tripling its available cash reserves to €1.31 million.

An Attractive Case for Investors

The company's newfound financial health is translating directly into shareholder value. The Board of Directors will propose a dividend of €0.11 per share at its upcoming General Meeting, a clear signal of confidence and a welcome return to a dividend policy. This follows a smaller €0.05 dividend for 2024, establishing a trend of sustainable shareholder returns.

Further bolstering the company's financial structure is a strategic move by its majority shareholder, ABL SA. The parent company plans to convert nearly all its dividends, amounting to €1.68 million, through a debt set-off. This maneuver effectively reinvests the capital back into ABL Diagnostics, strengthening its equity base and providing greater financial flexibility for future investments without diluting other shareholders.

This combination of explosive growth, positive net profitability, proven cash generation, and a shareholder-friendly dividend policy is what underpins Allinvest's bullish outlook. The firm's analysis points to a company that has successfully shifted its scale, streamlining its cost base while accelerating commercial activities—a difficult balance that many growth-stage companies fail to achieve.

Powering Growth Through Innovation and Alliances

ABL Diagnostics' financial success is not accidental; it is built on a foundation of cutting-edge technology and strategic partnerships that are expanding its market reach. The company's core offerings include its UltraGene range of molecular polymerase chain reaction (PCR) tests and its DeepChek® platform for genotyping by DNA sequencing. These technologies are critical for identifying and managing infectious diseases like HIV, Hepatitis, and Tuberculosis.

Allinvest's report highlights that the full impact of investments and partnerships forged in 2025 is yet to be realized, suggesting that the current growth trajectory could be sustainable. A pivotal development is the exclusive distribution agreement with Vela Diagnostics, a global provider of integrated molecular diagnostics solutions. As of January 2026, ABL Diagnostics became the sole distributor for Vela's CE-IVD certified automated PCR and Next-Generation Sequencing (NGS) platforms across Europe, the Middle East, and Africa.

This partnership is highly synergistic, combining Vela's automated sample-to-report workflows with ABL's specialized assay portfolio. It provides a comprehensive, clinically relevant solution for hospital and reference laboratories, reducing turnaround times and manual labor while increasing traceability. ABL Diagnostics has also taken over European logistics for Vela, ensuring faster delivery and better service for a combined, powerful offering in the diagnostics market.

Further synergies are being realized through an intra-group agreement with its sister company, CDL Pharma, whose products ABL Diagnostics began marketing in late 2025. This integrated strategy allows the company to present a unified and expansive portfolio to a global network of 57 distributors across 50 countries.

Navigating a Competitive Medtech Landscape

ABL Diagnostics operates in the highly competitive and rapidly growing European molecular diagnostics market, projected to expand at a steady pace over the next decade, with some estimates suggesting a CAGR of around 5%. This growth is fueled by an aging population, the rising prevalence of chronic and infectious diseases, and the increasing adoption of personalized medicine.

While the market is dominated by global giants like Roche Diagnostics, Qiagen, and bioMérieux, ABL Diagnostics has carved out a niche as an agile and innovative specialist. Its focus on genotyping and a broadening portfolio of microbiology assays, combined with integrated software solutions like its Nadis® patient record system, gives it a distinct edge. The partnership with Vela Diagnostics, in particular, enhances its ability to compete with larger players by offering a complete, automated platform solution.

The company's performance indicates it is successfully capitalizing on key market trends, such as the demand for syndromic multiplex testing and the shift toward automated, high-throughput platforms. By demonstrating both rapid growth and profitability, ABL Diagnostics is positioning itself not just as a survivor but as a formidable and expanding force in the European Medtech sector.